Richter sets up Chinese JV
Hungarian drug company Richter Gedeon on Monday said it established a joint venture in China. Richter owns a 51% stake in the JV. The rest is held by the owners of the company's marketing partner in China, Rxmidas Pharmaceuticals. The terms of the agreement on the JV include an upfront payment as well as milestone payments linked to any further increases in Richter's stake. Richter targets a "stronger direct presence" on the Chinese market with the JV. The new JV gives Richter seven regional offices and more than 200 staff in China.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.